<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236870</url>
  </required_header>
  <id_info>
    <org_study_id>P15-986</org_study_id>
    <nct_id>NCT03236870</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this non-interventional, observational study is to assess the effectiveness
      and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in
      real world clinical practice in China.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving at least a 75% reduction in Psoriasis Area Severity Index (PASI) relative to the baseline PASI score</measure>
    <time_frame>At Week 12</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>The DLQI is a self administered short, simple and practical dermatology-specific quality of life (QoL) questionnaire.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">181</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Participants with moderate to severe plaque psoriasis in China</arm_group_label>
    <description>Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderate to severe plaque psoriasis in China
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant who is in compliance with eligibility for adalimumab based on the local
             label;

          -  Moderate to severe plaque psoriasis patients eligible to use adalimumab according to
             the local label without any contraindication

          -  Patients have signed the authorization (or informed consent where applicable) to
             disclose and use personal health information after been prescribed with adalimumab.

        Exclusion Criteria:

          -  Patients who are pregnant or breast feeding at enrolment or wish to become pregnant
             during the following adalimumab treatment and within 150 days since adalimumab
             discontinuation;

          -  Patients in any psoriasis related clinical trial at the time of enrolment, at baseline
             or at any point during the study follow-up;

          -  Patients with active tuberculosis or other severe infections (e.g. sepsis and
             opportunistic infections) as well as moderate to severe cardiac insufficiency.

          -  Patients with difficulties for adequately reading, understanding and completing
             patient questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou 1st Muni People Hosp /ID# 208858</name>
      <address>
        <city>Guangzhou</city>
        <state>Anhui</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital /ID# 171398</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AbbVie China /ID# 151567</name>
      <address>
        <city>Shanghai</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong /ID# 169833</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <zip>830099</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital /ID# 169842</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital /ID# 169834</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University 3rd Hospital /ID# 213443</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital of southe /ID# 169830</name>
      <address>
        <city>Guangzhou</city>
        <zip>510018</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Aff. Hosp Harbin Med Univ /ID# 169827</name>
      <address>
        <city>Haerbin</city>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital /ID# 169841</name>
      <address>
        <city>Jinan</city>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tenth People's Hospital of /ID# 169831</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shantou University Medical College /ID# 209260</name>
      <address>
        <city>Shantou</city>
        <zip>515000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 7th People's Hospital of Shenyang /ID# 169829</name>
      <address>
        <city>Shenyang</city>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Hospital of Southern /ID# 169828</name>
      <address>
        <city>Shenzhen</city>
        <zip>518110</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jing Tai Tianjin Hospital Co.,Ltd /ID# 208201</name>
      <address>
        <city>Tianjin</city>
        <zip>300381</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>effectiveness</keyword>
  <keyword>safety</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

